Breaking News

Transpire Bio Opens Satellite R&D Facility in Shanghai

New site will focus on developing complex generic inhalation products for the EU/UK market and APAC market.

Author Image

By: Charlie Sternberg

Associate Editor

Transpire Bio Inc., an integrated clinical-stage biopharmaceutical company developing inhaled therapeutics for pulmonary and systemic diseases, opened its new satellite R&D facility in Shanghai, China on April 23rd. “As Transpire Bio continues to execute its strategic plan of building a legacy as an innovator in inhalation-based therapies, we are pleased to announce the grand opening of our Shanghai R&D center,” said Dr. Xian-Ming Zeng, CEO, Transpire Bio. “This team...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics